



Efficacy of tDCS in catatonic patients with Phelan McDermid syndrome, a case series



Keywords:

Catatonia
Phelan-McDermid syndrome
SHANK3
tDCS
Neurostimulation
Transcranial direct current stimulation
BFCRS
Neurodevelopmental disorder
Chronic catatonia

To the Editor:

Phelan-McDermid syndrome (PMS) is a rare disorder characterized by deletion or mutation of the *SHANK3* gene located in the chromosomal region 22q13.33. It is associated with catatonia in 53% of cases [1]. In neurodevelopmental disorders like PMS, under-diagnosis and lack of prompt management lead to chronicity of the catatonic episode [2], a factor associated with poor

therapeutic response to the two standard treatments: lorazepam and electroconvulsive therapy (ECT). Despite Expert Therapeutic Recommendations (<https://pmsf.org/>), effective and well-tolerated cares for chronic catatonia in PMS are still lacking. Furthermore, in PMS, benzodiazepines such as lorazepam, while reducing catatonic symptoms, may increase impulsivity, psychomotor arousal, confusion and insomnia limiting the use of this treatment [3]. ECT is also sometimes not available or contraindicated. Transcranial direct current stimulation (tDCS), an easy-to-apply noninvasive brain stimulation technique, has been shown to be effective and safe in neurodevelopmental disorders [4] and in twelve cases of catatonic patients [5]. In this letter, we present the efficacy and safety of tDCS in four cases of catatonia occurring on PMS.

The four cases are described in Table 1. The catatonic episode was diagnosed by two different clinicians according to the DSM-5 criteria. Severity was assessed by the Bush and Francis Catatonia Rating Scale (BFCRS). All participants received the same tDCS protocol that we previously reported as effective for schizophrenia and bipolar patients with catatonia [5], i.e. anode over the left dorsolateral prefrontal cortex (DLPFC, midway between F3 and FP1) and cathode over the left temporo-parietal junction (TPJ),

Table 1

Cases description. Chronic = more than 6 months. ASD = autism spectrum disorder. ID = intellectual disability.

Case/year	Age/Gender	Evolution/ Malignant features	Genetic profile	Other psychiatric diseases	Lorazepam /day	Others treatments	tDCS protocol	BFCRS (/69) before/mid/after/ discharge	BFCRS reduction mid/ after/delay
1/2020	21/M	Chronic/No	De novo mutation intron/exon junction	ASD, ID, bipolar disorder	15mg	lithium 1000mg melatonin 6mg	10 sessions 2/day	21/NA/16/10	NA/24%/52%
2/2020	23/F	Chronic/No	Del 22q13.33 55,9Kb	Dysphasia, bipolar disorder	18mg	lithium 1000mg	14 sessions 1/day	35/24/16/7	33%/54%/80%
3/2021	15/F	Chronic/No	De novo nonsens mut	ASD, ID	1mg	melatonin 3mg	20 sessions 2/day	16/10/5/NA	50%/69%/NA
4/2021	33/M	Chronic/No	Del 22q13.33 1,76Mb	ASD, ID, bipolar disorder	0mg	none	30 sessions 2/day	24/14/13/8	7%/46%/67%

Abbreviations: PMS, Phelan-McDermid syndrome; tDCS, transcranial direct current stimulation; ECT, Electroconvulsive therapy; DLPFC, Dorsolateral prefrontal cortex; TPJ, Temporo-Parietal Junction; BFCRS, Bush Francis Catatonia Rating Scale.




Fig. 1. BFCRS score reduction with tDCS course. Case 1 did not have a mid-treatment measure so a dotted line was added for understanding.

midway between T3 and P3). Stimulation was performed using a DC-stimulator plus (Neuroconn) with two 7×5 cm sponge electrodes soaked in a 0.9% saline solution. The stimulation level was set at 2 mA for 20 minutes. The sessions were conducted twice daily (separated by at least 3 hours), except for one patient who received only one session per day (case 2) (see Table 1). The present study was authorized by the local ethics committee under reference number D22-R003.

All four cases improved at each step of the tDCS course. After the last session of tDCS, the mean BFCRS reduction score was 48% (range: 24%–69%). However, patients continued to improve after tDCS and at discharge the mean BFCRS reduction score was 66% (range: 52%–80%) (see Fig. 1). With a one-tailed Wilcoxon test, we found a statistical difference between the pre- and post-cure BFCRS scores ($W = 15$, p -value = 0.027) and between the pre- and discharge BFCRS score ($W = 12$, p -value = 0.029). Tolerance was optimal. The only adverse events described were tingling and fatigue, and vomiting which was observed in one patient after one session.

In contrast to the pediatric catatonia rating scale, the BFCRS does not attribute points to regression symptoms that frequently occur in catatonia associated with genetic syndrome, underestimating the severity. This explains why the improvement reported by family and medical teams in the patients' environments was even greater than that measured by the BFCRS. Two out of 4 cases had a clear improvement of sphincter disorders at the end of the tDCS course. In all cases, tDCS resulted in an improvement of spontaneous speech. In one case, the patient was able to speak again after months of mutism, while in another case it improved his elocution and in a third one her vocabulary. The improvement in verbal language observed in some of these patients are similar to the improvement of post-stroke aphasia induced by tDCS treatment [6]. tDCS also resulted in tranquilization in all cases, with a strong reduction of impulsivity where lorazepam failed to improve in these particular patients with chronic catatonia [3].

Haploinsufficiency of *SHANK3* appears to be associated with the risk of catatonic syndrome [1]. *SHANK3* encodes a scaffolding protein of the postsynaptic density of glutamatergic excitatory synapses and its deficiency induces NMDA receptor (NMDAR) hypofunctionality [7]. Several authors argue for hypofunctionality of the glutamatergic system in catatonia [8]; while this system seems to have a crucial role in the neuroplasticity induced by tDCS [9]. In the case of catatonia associated with PMS, the action of tDCS on the glutamatergic system and in particular on NMDARs could be particularly important for the resolution of the episode. Moreover, we observe in this case series a persistent effect over time after treatment with tDCS. The hypothesis is that tDCS leads to long-lasting long term potentiation (LTP) inducing meta-

plasticity lasting for weeks [10]. However, two out of 4 cases (cases 1 and 2) showed a relapse of catatonia after several months, which argue for the interest of repetitive tDCS seances as it happens with some cases responsive to ECT.

With the observational design, we cannot exclude the placebo effect or confounding factors such as drugs, even though patients have very few treatments and no change during the duration of the whole protocol. The two patients receiving lithium during the tDCS course had a very good therapeutic response. Indeed, lithium is most likely to enhance tDCS efficacy as it does with rTMS [11] even though more studies are needed to evaluate the effect of lithium on tDCS. Two patients (cases 3 and 4) received low or no dose of benzodiazepam, mainly because of paradoxical agitation. Case 3, with the lowest dose of lorazepam per day, had the best BFCRS score reduction at the end of tDCS treatment. We can hypothesize that the poorer response of patients with higher doses of lorazepam is due to the well-known reduced efficacy of tDCS under benzodiazepines [12]. Our results suggest that the optimal treatment is about 20 sessions combined with lithium and benzodiazepine discontinuation on the morning of the tDCS sessions.

Despite the need for further studies to confirm the results, tDCS seems to be a good and safe therapeutic strategy for chronic catatonia in patients with PMS.

Declaration of competing interest

The Authors have declared that there are no conflicts of interest in relation to the subject of this study.

Acknowledgment

The present study was authorized by the local ethics committee under reference number D22-R003.

References

- [1] Kohlenberg TM, Trelles MP, McLarney B, Betancur C, Thurm A, Kolevzon A. Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. *J Neurodev Disord* 2020 Dec;12(1):7.
- [2] Benarous X, Raffin M, Ferrafiat V, Consoli A, Cohen D. Catatonia in children and adolescents: new perspectives. *Schizophr Res* 2018 Oct;200:56–67.
- [3] Kolevzon A, Delaby E, Berry-Kravis E, Buxbaum JD, Betancur C. Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature. *Mol Autism* 2019 Dec;10(1):50.
- [4] García-González S, Lugo-Marín J, Setien-Ramos I, Gisbert-Gustemps L, Arteaga-Henríquez G, Díez-Villoria E, et al. Transcranial direct current stimulation in Autism Spectrum Disorder: a systematic review and meta-analysis. *Eur Neuropsychopharmacol* 2021 Jul;48:89–109.
- [5] Haroche A. Efficacy of transcranial direct-current stimulation in catatonia: a review and case series. *Front Psychiatr* 2022;13:9.

- [6] Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke. *Cochrane Database Syst Rev* [Internet] Cochrane Stroke Group 2019 May 21;(5):1–93. CD009760. [cited 2022 Jun 13]; Available from: <https://doi.wiley.com/10.1002/14651858.CD009760.pub4>.
- [7] Duffney LJ, Wei J, Cheng J, Liu W, Smith KR, Kittler JT, et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. *J Neurosci* 2013 Oct 2;33(40):15767–78.
- [8] Rogers JP, Pollak TA, Blackman G, David AS. Catatonia and the immune system: a review. *Lancet Psychiatr* 2019 Jul;6(7):620–30.
- [9] Hunter MA, Coffman BA, Gasparovic C, Calhoun VD, Trumbo MC, Clark VP. Baseline effects of transcranial direct current stimulation on glutamatergic neurotransmission and large-scale network connectivity. *Brain Res* 2015 Jan;1594:92–107.
- [10] Cirillo G, Di Pino G, Capone F, Ranieri F, Florio L, Todisco V, et al. Neurobiological after-effects of non-invasive brain stimulation. *Brain Stimul* 2017 Jan;10(1):1–18.
- [11] Martinotti G, Montemitro C, Pettorruso M, Viceconte D, Alessi MC, Di Carlo F, et al. Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability. *Expet Opin Pharmacother* 2019 Sep 2;20(13):1575–88.
- [12] Goerigk SA, Padberg F, Bühner M, Sarubin N, Kaster TS, Daskalakis ZJ, et al. Distinct trajectories of response to prefrontal tDCS in major depression: results from a 3-arm randomized controlled trial. *Neuropsychopharmacology* 2021 Mar;46(4):774–82.

Mylène Moyal*, Marion Plaze

GHU PARIS Psychiatrie & Neurosciences, Sainte-Anne Hospital, F-75014, Paris, France

Université Paris Cité, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR S1266, Paris, France

Ambre Baruchet

GHU PARIS Psychiatrie & Neurosciences, Sainte-Anne Hospital, F-75014, Paris, France

David Attali

GHU PARIS Psychiatrie & Neurosciences, Sainte-Anne Hospital, F-75014, Paris, France

Physics for Medicine Paris, INSERM U1273, CNRS UMR 8063, ESPCI Paris, PSL University, F-75012, Paris, France

Cora Cravero

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France

Interdepartmental Mobile Unit for Complex Situations in Autism (UMI 75-92), Elan Retrouvé Foundation, F-75015, Paris, France

Marie Raffin

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France

GRC-15, Dimensional Approach of Child and Adolescent Psychotic Episodes, Faculté de Médecine, Sorbonne Université, Paris, France

Angèle Consoli

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France

GRC-15, Dimensional Approach of Child and Adolescent Psychotic Episodes, Faculté de Médecine, Sorbonne Université, Paris, France

David Cohen

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France

CNRS UMR 7222, Institute for Intelligent Systems and Robotics, Sorbonne Université, UPMC, Paris, France

Alexandre Haroche¹

GHU PARIS Psychiatrie & Neurosciences, Sainte-Anne Hospital, F-75014, Paris, France

Boris Chaumette¹

GHU PARIS Psychiatrie & Neurosciences, Sainte-Anne Hospital, F-75014, Paris, France

Université Paris Cité, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR S1266, Paris, France

Department of Psychiatry, McGill University, Montreal, Canada

* Corresponding author. Sainte-Anne hospital, GHU Paris Psychiatrie & Neurosciences, 1 rue Cabanis, 75014, Paris, France. E-mail address: m.moyal@ghu-paris.fr (M. Moyal).

10 October 2022

Available online 26 October 2022

¹ These authors contribute equally to this work.